World Journal of Urology

, Volume 21, Issue 5, pp 311–315 | Cite as

A new oral testosterone undecanoate formulation

  • Frank-Michael KöhnEmail author
  • Wolf-Bernhard Schill
Topic Paper


Testosterone undecanoate has been available on the market for more than 20 years. This testosterone ester is used worldwide for oral treatment of male hypogonadism. So far, testosterone undecanoate has been dissolved in oleic acid, leading to inconvenient storage conditions. It will now be available in a new formulation with castor oil and propylene glycol laurate instead of oleic acid, thus improving storage conditions markedly (stable at room temperature for approximately 3 years). Pharmacokinetic and pharmacodynamic studies have demonstrated bioequivalence of the old and the new formulation of testosterone undecanoate. Therefore, the results of studies that were performed with the old formulation can be transferred to the clinical use of the new formulation. Controlled studies have shown its efficacy in the treatment of symptoms associated with reduced serum testosterone levels. In these cases testosterone undecanoate improves bone mineral density, quality of life, muscle mass, libido and mood. Further studies will help evaluate the efficacy and safety of the new formulation in the treatment of elderly men with late-onset hypogonadism.


Testosterone undecanoate Hypogonadism Therapy Aging male Substitution 


  1. 1.
    Abdelmassih R, Dhont M, Comhaire F (1992) Pilot study with 120 mg Andriol treatment for couples with a low fertilization rate during in-vitro fertilization. Hum Reprod 7:267–268PubMedGoogle Scholar
  2. 2.
    Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R (1994) Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate. Arch Dis Child 71:315–317PubMedGoogle Scholar
  3. 3.
    Anawalt BD, Amory JK, Wang C, Swerdloff RS, Dobs AS, Meikle AW, Elbers JMH, Houwing NS (2002) A pharmacokinetic study of oral testosterone undecanoate (Org 538). J Androl [Suppl]: 37Google Scholar
  4. 4.
    Bagchus WM, Mink CPA, Maris F, Houwing NS (2001) Bioequivalence of Andriol® and Andriol® Testocaps™. Aging Male 4:259Google Scholar
  5. 5.
    Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319–325PubMedGoogle Scholar
  6. 6.
    Boyanov MA, Boneva Z, Christov VG (2003) Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6:1–7PubMedGoogle Scholar
  7. 7.
    Brown DC, Butler GE, Kelnar CJ, Wu FC (1995) A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for age, prepubertal boys. Arch Dis Child 73:131–135PubMedGoogle Scholar
  8. 8.
    Butler GE, Sellar RE, Walker RF, Hendry M, Kelnar CJ, Wu FC (1992) Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 75:37–44PubMedGoogle Scholar
  9. 9.
    Comhaire F (1990) Treatment of idiopathic testicular failure with high-dose testosterone undecanoate: a double-blind pilot study. Fertil Steril 54:689–693PubMedGoogle Scholar
  10. 10.
    Comhaire F, Schoonjans F, Abdelmassih R, Gordts S, Campo R, Dhont M, Milingos S, Gerris J (1995) Does treatment with testosterone undecanoate improve the in-vitro fertilizing capacity of spermatozoa in patients with idiopathic testicular failure? (results of a double blind study). Hum Reprod 10:2600–2602PubMedGoogle Scholar
  11. 11.
    Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11:247–264PubMedGoogle Scholar
  12. 12.
    Cutolo M, Balleari E, Giusti M, Intra E, Accardo S (1991) Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 34:1–5PubMedGoogle Scholar
  13. 13.
    Geurts TBP, Coelingh Bennink HJT (2000) Testosterone replacement therapy—testosterone undecanoate (Andriol®). J Urol Urogynaekol 1[Special Edition]: 24–35Google Scholar
  14. 14.
    Gooren LJG (1994) A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 15:212–215PubMedGoogle Scholar
  15. 15.
    Gregoriou O, Papadias C, Gargaropoulos A, Konidaris S, Kontogeorgi Z, Kalampokas E (1993) Treatment of idiopathic infertility with testosterone undecanoate. A double blind study. Clin Exp Obstet Gynecol 20:9–12PubMedGoogle Scholar
  16. 16.
    Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82:3793–3796PubMedGoogle Scholar
  17. 17.
    Horst HJ, Höltje WJ, Dennis M, Coert A, Geelen J, Voigt KD (1976) Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr 54:875–879PubMedGoogle Scholar
  18. 18.
    Jeantils V, Nguyen G, Bacle F, Thomas M, Krivitsky A (1993) Weight gain under testosterone undecanoate in AIDS. Therapie 48:71–72PubMedGoogle Scholar
  19. 19.
    Jockenhovel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Muller-Wieland D, Krone W (1999) Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48:590–596PubMedGoogle Scholar
  20. 20.
    Kalinchenko SY, Kozlow GI, Gontcharow, Katsiya GV (2003) Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 6:94–99PubMedGoogle Scholar
  21. 21.
    Kloer H, Hoogen H, Nieschlag E (1980) Trial of high-dose testosterone undecanoate in treatment of male infertility. Int J Androl 3:121–129PubMedGoogle Scholar
  22. 22.
    Li JY, Zhu JC, Dou JT, Bai WJ, Deng SM, Li M, Huang W, Jin H (2002) Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male 5:47–51PubMedGoogle Scholar
  23. 23.
    Luisi M, Franchi F (1980) Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest 3:305–308Google Scholar
  24. 24.
    Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991–997PubMedGoogle Scholar
  25. 25.
    Morales A, Lunenfeld B (2002) Investigation, treatment and monitorino of late-onset hypogonadism in males. Aging Male 5:74–86PubMedGoogle Scholar
  26. 26.
    Papadimas J, Bili E, Papadopoulo E, Spanos E, Tarlatzis B, Kokkas B (1996) Testosterone undecanoate versus mesterolone in hypogonadal patients. Rev Clin Pharmacol Pharmacokinet Int 10:3–8Google Scholar
  27. 27.
    Park NC, Yan BQ, Chung JM, Lee KM (2003) Oral testosterone undecanoate (Andriol®) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male 6:86–93PubMedGoogle Scholar
  28. 28.
    Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV (2002) Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 25:119–125CrossRefPubMedGoogle Scholar
  29. 29.
    Pusch HH (1989) Oral treatment of oligozoospermia with testosterone-undecanoate: results of a double-blind-placebo-controlled trial. Andrologia 21:76–82PubMedGoogle Scholar
  30. 30.
    Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhövel F (2003) Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 60:21–28CrossRefPubMedGoogle Scholar
  31. 31.
    Schürmeyer T, Wickings EJ, Freischem CW, Nieschlag E (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 102:456–462PubMedGoogle Scholar
  32. 32.
    Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Porter CJH, Charman WN (2003) The contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol® formulations in conscious lymph-duct cannulated dogs. J Pharmacol Exp Ther 306:1–9CrossRefPubMedGoogle Scholar
  33. 33.
    Skakkebaek NE, Bancroft J, Davidson DW, Warner P (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 14:49–61Google Scholar
  34. 34.
    Tan RS, Pu SJ (2003) A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male 6:13–17PubMedGoogle Scholar
  35. 35.
    Täuber U, Schröder K, Düsterberg B, Matthes H (1986) Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet 11:145–149PubMedGoogle Scholar
  36. 36.
    Uyanik BS, Ari Z, Gumus B, Yigitoglu MR, Arslan T (1997) Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Jpn Heart J 38:73–82PubMedGoogle Scholar
  37. 37.
    Vandekerckhove P, Lilford R, Vail A, Hughes E (2000) Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2:CD000150PubMedGoogle Scholar
  38. 38.
    Vermeulen A, Kaufman JM (2002) Diagnosis of hypogonadism in the aging male. Aging Male 5:170–176PubMedGoogle Scholar
  39. 39.
    Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol 58A: 618–625Google Scholar
  40. 40.
    Wu S, Weng X (1992) Therapeutic effect of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients. Chin Med Sci J 7:137–141PubMedGoogle Scholar
  41. 41.
    Wu SZ, Weng XZ (1993) Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl) 106:415–418Google Scholar
  42. 42.
    Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E (2003) Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88:2049–2054CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Department of Dermatology and AllergologyTechnical UniversityMunichGermany
  2. 2.Center of Dermatology and AndrologyJustus Liebig UniversityGiessenGermany

Personalised recommendations